Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06098079 · ClinicalTrials.gov registry record · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Phase 4 study of Obesity, sponsored by Currax Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 8,600
- Enrollment target
- 20
- Study locations
NCT06098079: Recruiting Phase 4 study of Obesity, sponsored by Currax Pharmaceuticals.
NCT06098079 is a Phase 4 study of Obesity that is actively recruiting participants, run by Currax Pharmaceuticals. The registered enrollment target is 8,600 participants, above the 811-participant average among 1,053 other Obesity trials with a reported enrollment target (960% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06098079, a Phase 4 study of Obesity, is actively recruiting participants, sponsored by Currax Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 8,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Primary Outcome
Occurrence of cardiovascular death in number of study patients receiving NB compared with number of study patients receiving placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone-Bupropion (NB) Combination
Study Locations (20)
California
- Velocity Clinical Research, Gardena - Anderson
- Velocity Clinical Research - Chula Vista
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research, San Diego - La Mesa
- Chemidox Clinical Trials Inc. - Lancaster
- Long Beach Clinical Trials - Long Beach
- Velocity Clinical Research - Los Angeles
- Valley Vitality Ventures - Manteca
- National Institute of Clinical Research, Inc. - Pomona
Arizona
- Sun City Research - Glendale
- Cardiovascular Consultants/NextStage Clinical Research - Glendale
- Desert Clinical Research - Mesa
- Velocity Clinical Research, Phoenix - Phoenix
- Fiel Family & Sports Medicine CCT Research - Tempe
- Synexus Clinical Research US; Inc. - Tucson
Alabama
- TrialMed Birmingham (DRS) - Birmingham
- Accel Research Sites Network - Birmingham
- Cullman Clinical Trials - Cullman
- AMR Mobile - Mobile
- Velocity Clinical Research, Mobile - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,600 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2029-07 |
| Phase | Phase 4 |
What NCT06098079 shows while recruiting
NCT06098079 is an interventional study that assigns participants to a tested intervention. Its 8,600 participants enrollment target places it among the larger protocols in the corpus, above the 811-participant average among 1,053 other Obesity trials with a reported enrollment target (960% higher).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06098079 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06098079 about?
NCT06098079 is a clinical study titled "Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)". A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
What is the current status of trial NCT06098079?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 8,600 participants. The study started on 2024-01-03. Estimated completion is 2029-07.
What conditions does trial NCT06098079 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06098079?
The interventions under investigation include: Placebo (DRUG), Naltrexone-Bupropion (NB) Combination (DRUG).
Who is sponsoring clinical trial NCT06098079?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06098079 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06098079's enrollment target sits among peer trials
8,600 9th of 1053 higher than 1,045 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
A Study of a Novel Precision Medicine Approach For Obesity
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI